Q122 SCS Market revenues were up in the low-single digit YoY, but pandemic-related issues made it a bumpy ride
For Q122, the spinal cord stimulation (SCS) market was up in the low-single digits YoY in both the US and WW, but pandemic-related issues made it a bumpy ride. The market was down from pre-pandemic levels for most competitors, still weakened by pandemic disruption, staffing issues and a limping recovery.
Among the many topics covered in detail in our comprehensive Q122 Spinal Cord Stimulation Market Recap* are:
- Complete Q122 Spinal Cord Stimulation Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Market News including Revenues, Data, Charts and Shares
- Top Competitor Results & Highlights
- Important Q122 SCS News and Events
A surge in Omicron cases late in Q421 continued into January Q122 before dropping again in February, impacting revenues for some competitors more than others depending on ...
Read the entire Q122 Spinal Cord Stimulation Market Recap, including news, data, charts, company revenues, shares and our expert analysis*
*The entire unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK is the leading source of competitive intelligence used by the top ten global wound care & orthopedics companies. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.